Enveric Biosciences, Inc. ENVB
1.50
(0.05)
(3.23%)
as of 25 Sep
- Market cap
- $6.9M
- P/E
- 0.0×
Follow ENVB
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
P/S ratio |
31,776,179.26 | 12,862,075.64 | 0.00 | 18.35 | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
P/Operating CF |
3,912,019,976.16 | (664,062,733.74) | 0.00 | 886.17 | — | — | — | — | — | — |
P/B ratio |
98,504,220.80 | 32,144,241.44 | 0.00 | 0.00 | — | — | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
EV/Sales |
31,776,179.74 | 12,862,075.69 | 0.12 | 18.47 | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 1.06 | 25.76 | — | — | — | — | — | — |
EV/Operating CF |
(424,766,672.43) | (228,041,392.04) | (1.98) | (1,138.03) | — | — | — | — | — | — |
EV/FCF |
(420,244,075.32) | (159,593,454.87) | (1.09) | (258.97) | — | — | — | — | — | — |
Quick Ratio |
0.74 | 0.45 | 0.63 | 3.35 | 2.32 | 6.34 | 4.44 | 0.98 | 1.50 | 5.09 |
Current Ratio |
0.79 | 0.48 | 0.69 | 0.06 | 3.35 | 6.48 | 4.61 | 1.53 | 1.84 | 5.38 |
Net Debt/EBITDA |
(4.29) | (0.30) | 0.80 | (0.31) | 0.30 | 0.68 | 0.90 | 0.14 | 0.24 | 0.55 |
Debt/Assets |
47.15% | 13.76% | 17.57% | 680.42% | 0.00% | 0.66% | 0.33% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
1.60 | 0.37 | 0.48 | (0.41) | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
1.36 | 1.06 | 1.05 | 2.68 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.97 | 0.25 | 0.13 | 0.27 | 0.57 | 0.23 | 0.91 | 0.81 | 0.81 | 0.67 |
Capex/Depreciation |
(0.02) | 0.00 | 0.00 | (1.23) | 0.00 | 0.00 | (0.07) | 0.03 | 0.00 | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (46.66%) | (71.78%) | (129.02%) | (53.93%) | (875.21%) | (381.31%) | (101.68%) | (209.99%) | (539.57%) | (420.48%) | |
| (10.43%) | (24.35%) | (47.61%) | (16.21%) | (326.45%) | (317.87%) | (81.26%) | (146.39%) | (259.40%) | (296.67%) | |
ROIC |
(11.63%) | (31.31%) | (30.60%) | 0.00% | (191.11%) | (787.91%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
109.31% | 71.44% | 426.39% | 139.47% | (429.61%) | (320.24%) | (124.39%) | (1,000.28%) | (617.46%) | (290.40%) |
Average Days of Receivables |
81.39 | 66.39 | 66.82 | 58.38 | — | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
25.90% | 38.09% | 25.11% | 5.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.65 | 0.60 | 0.66 | 159.14 | 0.44 | 0.32 | 0.02 | 0.05 | 0.01 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 1.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 23,967.29 | — | — | — | — | — | — |
Earnings Yield |
0.00% | (0.39%) | (18.39%) | (0.69%) | — | — | — | — | — | — |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | (0.39%) | — | — | — | — | — | — |
Revenue per Share |
2.77 | 3.24 | 0.00 | 66,524.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.21) | (0.18) | 0.00 | (1,079.83) | (6,481.33) | (4,406.81) | (2,143.34) | (1,174.53) | (184.39) | (24.32) |
Capex per Share |
0.00 | 0.00 | 0.00 | (140.50) | 0.00 | (72.96) | (73.02) | 0.98 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.21) | (0.18) | 0.00 | (1,220.33) | (6,481.33) | (4,479.77) | (2,216.36) | (1,173.56) | (184.39) | (24.32) |
Cash per Share |
0.11 | 0.33 | 0.00 | 72.83 | 2,630.83 | 6,675.38 | 2,215.49 | 190.67 | 53.48 | 13.98 |
Shareholders Equity per Share |
0.89 | 1.30 | 0.00 | (3,019.33) | 5,692.67 | 8,579.19 | 1,833.99 | 163.03 | 38.01 | 12.48 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.89 | 1.30 | 0.00 | (3,019.33) | 5,692.67 | 8,579.19 | 1,833.99 | 163.03 | 38.01 | 12.48 |
Free Cash Flow |
(2.73) | (2.75) | (2.56) | (0.73) | (3.89) | (11.65) | (17.73) | (14.08) | (7.73) | (8.14) |
Working Capital |
(2.64) | (15.72) | (4.63) | (1.81) | 1.60 | 15.00 | 14.44 | 1.24 | 1.24 | 4.02 |
Capital Expenditures |
(0.03) | 0.00 | 0.01 | (0.08) | (0.04) | (0.19) | (0.58) | 0.01 | — | — |
Net Current Asset Value |
(17.78) | (18.10) | (8.82) | (1.81) | 1.60 | 13.32 | 13.55 | 1.24 | 1.24 | 4.02 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | — |
Net Profit Margin |
(7.69%) | (22.97%) | (45.31%) | (6.04%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 25.64 | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
13.58 | 33.87 | 202.75 | 0.82 | 0.00 | 133.70 | 11.64 | 0.80 | 1.10 | 1.26 |
Cash ROIC |
(8.85%) | (9.00%) | (15.14%) | 71.14% | (77.87%) | (29.50%) | (54.91%) | (344.03%) | (209.50%) | (93.74%) |
Accounts Receivable Turnover |
5.59 | 5.75 | 5.15 | 5.60 | — | — | — | — | — | — |
Accounts Payable Turnover |
7.56 | 7.34 | 7.01 | 11.48 | 0.13 | 1.00 | 0.76 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
64.10 | 50.67 | 46.98 | 13.30 | 2,056.86 | 365.96 | 388.57 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
6.47 | 8.45 | 8.35 | 7.13 | — | — | — | — | — | — |
Average Payables |
3.86 | 5.23 | 4.85 | 2.77 | 0.92 | 0.68 | 0.57 | 0.84 | 0.87 | 0.55 |
Average Assets |
26.67 | 45.85 | 40.92 | 14.87 | 2.10 | 15.41 | 23.14 | 11.93 | 3.69 | 4.09 |
Average Common Equity |
5.96 | 15.55 | 15.10 | 4.47 | 0.78 | 12.84 | 18.49 | 8.31 | 1.77 | 2.89 |
Columns are period end dates